REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Anacetrapib (Primary) ; Atorvastatin
- Indications Atherosclerosis; Cardiovascular disorders; Coronary disorders
- Focus Registrational; Therapeutic Use
- Acronyms REVEAL
- 15 Dec 2021 Results efficacy and safety results from an additional 2 years of follow-up following the discontinuation of the randomized anacetrapib treatment or matching placebo in REVEAL published in the European Heart Journal
- 13 Aug 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 03 Jul 2020 This trial is completed in Denmark, according to European Clinical Trials Database record.